Einsatz hämatopoetischer Wachstumsfaktoren in der Therapie hämatologischer und onkologischer Krankheiten

Onkologie

Volumn 21, Issue 6, 1998, Pages 527-532

  Grell, R ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Acute leukemia; Bone marrow transplantation; Cost benefit efficacy; Febrile neutropenia (FNP); G CSF; GM CSF; Infection; Myelodysplasia

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

ACUTE LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; FEBRILE NEUTROPENIA; HUMAN; INFECTION; MYELODYSPLASIA; PROPHYLAXIS; REVIEW;

EID: 0032414731     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Review article. Blood 1996;88:3675-3685.
2. Fey MF, Tobler A: Haematopoietic myeloid growth factors in the treatment of acute myelogenous leukaemia: Players on or off stage? Onkologie 199720: 372-377.
3. Buchner T, Hiddemann W, Wormann B, Zuhlsdorf M, Rottmann R, Innig G, Maschmeier G, Ludwig WD, Sauerland MC, Heinecke A: Hematopoietic growth factors in acute myeloid leukemia: Supportive evidence and priming effects. Semin Oncol 199724: 124-131.
4. Oncology, ASCO: American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1994;12: 2471-2508.
5. Greil R: The application of G-CSF and GM-CSF as an adjunct to chemotherapy in clinical practice: perspectives and challenges. Onkologie 1993;16:310-328.
6. Ohno R, Hiraoka A, Tanimoto M, Asou N, Kuriyama K, Kobayashi T, Yoshida M, Teshima H, Saito H, Fujimoto K: No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-treatening infection during remission induction and consolidation therapy. Blood 1993;81: 561-562.
7. Negrin RS, Haeuber DH, Nagler AEA: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990;76J6-43.
8. Gerhartz HH, Zwierzina H, Suciu S, Walther J, Dardenne M, Neuwirtova R, Fenaux P, Beksac M, Harousscau JL. Louwagie A, Thyss A, Here D, Coiffier B, Baumelou F, Lager B, Solbu G, Willemze R: Randomized 3-arm phase III study of interleukin-3 (IL-3) or granulocyte/macrophage colonystimulating factor (GM-CSF) as an adjunct to low doses of cytosine arabinoside (LD-Ara-C) for the treatment of high-risk myelodysplastic syndromes (HR-MDS) [370]. Blood 1997;90(suppll):85a.
9. Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM: Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J NatI Cancer Inst 1992;84: 1201-1203.
10. Geissler K, Koller E, Hubman E, Niederwieser D, Hinterberger V, Geissler D, Kyrie P, Knobl P, Pabinger I, Thalhammer R, Schwarzinger I, Manhalter C Jaeger U, Heinz R, Linkesch W, Lechner K: Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - A randomized phase III study. Blood 1997;9ft590-596.
11. Oltmann OG, Hoelzer D, Graden E, Ganser A, Kelly K, Reutzel R, Lipp T, Busch FW, Schwänzen M, Heil G, et al: Concomitant granulocyte colonystimulating factor and induction chemoradiotherapy in adult acute lymphoblastik leukemia: A randomized phase III trial. Blood 1995;86:444-450.
12. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock LM, Sandlund JT, Relling MV, Ribeiro RC, Crist WM, Evans WE: Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997 36:1781-1787.
13. Weite K, Reiter A, Mempel KEA: A randomized phase-Ill study of the efficacy of granulocyte colonystimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group Blood 1996;87:3143-3150.
14. Kaplan LD, Kahn JO, Crowe F, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding PA: Clinical and virologie effects of recombinant human granulocyte-macrophage colonystimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial. J Clin Oncol 1991;9:929-940.